Clinical Trial Update: VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the combination of a VA agent with a PD-1 inhibitor for relapsed or refractory acute myeloid leukemia and high-risk myelo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• PD-1 inhibitor

Snippet

Sponsor: Beijing 302 Hospital | Conditions: Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 2 | Status: RECRUITING